These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38554946)

  • 21. EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy.
    Liu Y; Scrivano L; Peterson JD; Fens MHAM; Hernández IB; Mesquita B; Toraño JS; Hennink WE; van Nostrum CF; Oliveira S
    Mol Pharm; 2020 Apr; 17(4):1276-1292. PubMed ID: 32142290
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer.
    Ashton JR; Gottlin EB; Patz EF; West JL; Badea CT
    PLoS One; 2018; 13(11):e0206950. PubMed ID: 30408128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.
    Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A
    Front Immunol; 2021; 12():838082. PubMed ID: 35116045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
    Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
    Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.
    Pedersen DV; Rösner T; Hansen AG; Andersen KR; Thiel S; Andersen GR; Valerius T; Laursen NS
    Mol Immunol; 2020 Aug; 124():200-210. PubMed ID: 32599335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
    J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
    McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
    Front Immunol; 2022; 13():864868. PubMed ID: 35935988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery.
    Pham TC; Jayasinghe MK; Pham TT; Yang Y; Wei L; Usman WM; Chen H; Pirisinu M; Gong J; Kim S; Peng B; Wang W; Chan C; Ma V; Nguyen NTH; Kappei D; Nguyen XH; Cho WC; Shi J; Le MTN
    J Extracell Vesicles; 2021 Feb; 10(4):e12057. PubMed ID: 33643546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
    van Lith SAM; van den Brand D; Wallbrecher R; Wübbeke L; van Duijnhoven SMJ; Mäkinen PI; Hoogstad-van Evert JS; Massuger L; Ylä-Herttuala S; Brock R; Leenders WPJ
    Eur J Pharm Biopharm; 2018 Mar; 124():63-72. PubMed ID: 29274374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking EGFR Activation with Anti-EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms.
    Guardiola S; Varese M; Sánchez-Navarro M; Vincke C; Teixidó M; García J; Muyldermans S; Giralt E
    Angew Chem Int Ed Engl; 2018 Oct; 57(42):13843-13847. PubMed ID: 30152597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
    Tijink BM; Laeremans T; Budde M; Stigter-van Walsum M; Dreier T; de Haard HJ; Leemans CR; van Dongen GA
    Mol Cancer Ther; 2008 Aug; 7(8):2288-97. PubMed ID: 18723476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
    Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
    Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity.
    Bakherad H; Farahmand M; Setayesh N; Ebrahim-Habibi A
    Life Sci; 2020 Sep; 257():118052. PubMed ID: 32634431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.
    Vosjan MJ; Perk LR; Roovers RC; Visser GW; Stigter-van Walsum M; van Bergen En Henegouwen PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):753-63. PubMed ID: 21210114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
    D'Huyvetter M; Xavier C; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1939-54. PubMed ID: 25035968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
    Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
    J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.
    Koromyslova AD; Devant JM; Kilic T; Sabin CD; Malak V; Hansman GS
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis.
    Van Impe K; Bethuyne J; Cool S; Impens F; Ruano-Gallego D; De Wever O; Vanloo B; Van Troys M; Lambein K; Boucherie C; Martens E; Zwaenepoel O; Hassanzadeh-Ghassabeh G; Vandekerckhove J; Gevaert K; Fernández LÁ; Sanders NN; Gettemans J
    Breast Cancer Res; 2013 Dec; 15(6):R116. PubMed ID: 24330716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.